All assets associated with the tag: HIV
Research shows that in addition to HIV’s ability to lay dormant in the blood/lymphoid system, the virus may also lay dormant in the central nervous system, delineating another challenge in creating a cure.
The long fight to end HIV/AIDS has seen real progress spurred by innovative research, prevention, treatment and education. But our nation's ambitious goal of ending the HIV epidemic by 2030 is nevertheless in peril. Here are ways to step up the fight.
An experimental HIV vaccine has been found to induce broadly neutralizing antibody precursors among a small group of volunteers in a Phase 1 study. The findings suggest that a two-dose regimen of the vaccine, given eight weeks apart, can elicit immune responses against the human immunodeficiency virus.
An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.
Researchers at Duke have published new work in a scientific journal, showing that a potential HIV vaccine component proves effective in primate study.
New research shows people living with HIV are twice as likely to be hospitalized if they get monkeypox.
Joe Fisher, WRAL reporter
The funding is helping Duke researchers create detailed HIV models to help develop new therapies and vaccines.
The funding is helping researchers create detailed HIV models to help develop new therapies and vaccines.
Rick Armstrong, WRAL photojournalist
Duke will receive a $27 million federal grant over five years to build structural models of the virus that causes AIDS to guide development of new vaccines.
Drug giant GlaxoSmithKline earned two victories in the ongoing battle to treat AIDS, one involving a patent settlement and the other securing FDA approval for a long-term HIV treatment from GSK-owned ViiV Healthcare.
On Dec. 20, the FDA approved a new drug called Apretude. It is used as pre-exposure prevention (PrEP) against HIV and, as a long-acting injectable medication, is the first of its kind.
The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday. The drug has roots in North Carolina.
The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday. And the drug has roots in North Carolina,
The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV. UNC-CH is among the recipients.
Ed Browne, PhD, assistant professor of medicine, is the principal investigator of a $4-million, 5-year study of the role of cannabis use in HIV latency – one of the main barriers toward curing people with the infection.
Billy Porter made history by winning an Emmy in 2019 for his role as Pray Tell, a character who is HIV-positive, on the FX series "Pose."
By Lisa Respers France, CNN
Patients claim that Gilead's HIV medication TDF has led to multiple serious side effects. Gilead alleged withheld a safer alternative in order to maximize their own profits, putting patients at risk.
Abbey Slattery, WRAL Digital Solutions
U.S. regulators have approved the first long-acting drug combo for HIV, monthly shots that can replace the daily pills now used to control infection with the AIDS virus.
ViiV Healthcare, which has a major presence in RTP, has secured European Union approval for its once-a-month treatment of HIV, offering an alternative to daily care.
The HIV Prevention Trials Network has won a seven-year funding agreement with the US National Institutes of Health, the latest agreement in a series of awards dating back more than a decade.
An injectable drug from ViiV Healthcare has proved to be much more effective in preventing HIV among women than a currently daily pill treatment, ViiV announced early Monday.
After a five-month battle with leukemia, the first known person to be cured of HIV has died of cancer, according to the International AIDS Society.
The public-private collaboration provides continued funding for HIV Cure Center and Qura Therapeutics, the joint venture that brings academic and pharmaceutical research scientists together .
A “major step” toward a possible cure for HIV with a technique that targets the virus as it lays dormant in people receiving treatment thus escaping being attacked by current therapy.
ViiV Healthcare, which has a large research and development operation in RTP, has filed for approval of an AIDS treatment that would help people infected with HIV who have developed a resistance or intolerance to other medications.
